Skip to content

Water for injection

DRUG19 trials

Sponsors

HAL Allergy B.V., Azienda Unita Sanitaria Locale Toscana Nord Ovest, Tourmaline Bio Inc., Epifarma S.r.l., Carmel Medical Center

Conditions

BiomarkersCOVID 19Degenerative Disc DiseaseGingivitisGram-Negative Bacteria InfectionGynecological LaparoscopyHidradenitis SuppurativaInfant, Newborn, Diseases

Early Phase 1

Phase 1

Phase 2

Phase 3

Pain Relief by Intra-Peritoneal Nebulization of Ropivacaine Under Remifentanil Anesthesia for Gynecological Laparoscopy
CompletedNCT00927979
Carmel Medical CenterGynecological Laparoscopy
Start: 2009-06-30End: 2010-10-31Updated: 2011-06-28
Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System
CompletedNCT03345992
Hellenic Institute for the Study of SepsisBiomarkers, Gram-Negative Bacteria Infection, Mortality +4
Start: 2017-12-15End: 2020-12-19Updated: 2020-12-22
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects with Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
Active, not recruitingCTIS2023-504942-75-01
HAL Allergy B.V.Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
Start: 2024-08-22Target: 582Updated: 2025-12-16
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of pre-surgical HPV9-valente vaccination in women treated with loop electrosurgical excision (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2+) up to cervical cancer initially invasive (FIGO IA1) - HOPE 9 STUDY
CompletedCTIS2024-513704-34-00
Azienda Unita Sanitaria Locale Toscana Nord Ovestcervical cancer
Start: 2021-10-01End: 2025-12-15Target: 1220Updated: 2024-06-24
Randomized, double-blind, parallel-groups, active - and placebo-controlled study to Evaluate the efficacy of a fixed combination of diclofenac 75 mg + thiocolchicoside 4 mg as solution for injection, in reLIEving back pain symptoms. Controlled study vs. dicloFenac 75 mg solution for injection and placebo. RELIEF Study
CompletedCTIS2024-518753-42-00
Epifarma S.r.l.as well as to improve mobility and physical function., Low back pain (LBP). LBP is one of the most frequent and disabling health problems. It is estimated that about 80% of adults will experience an episode of acute or chronic LBP at least once during their lifetime The mechanism underlying acute LBP may be disk-, muscle- or posterior articulation related. The aim of the treatment is always to obtain early and maximum relief of the local and regional pain
Start: 2023-03-30End: 2025-06-10Target: 216Updated: 2025-06-12

Phase 4

Unknown Phase

Related Papers